Expected News From Circular17 Aug 2020 09:11
SCIB1 ...
. Following regulatory approval, patient screening was initiated in the UK,
with Professor Poulam Patel, Professor of Clinical Oncology at the University of Nottingham as the Chief
Investigator for the global study; however the impact of COVID-19 means other sites will be initiated later in
the second half of 2020. Subject to completion of the Capital Raise, site initiation is expected to be focussed
in the UK initially with commencement of patient enrolment later in the second half of 2020, with interim
clinical data expected in the first half of 2021.
Modi1
The Company continues to
progress the necessary processes and documentation required for regulatory submission to start the
planned clinical study in the UK in the first half of 2021, with clinical trial application targeted for the fourth
quarter of 2020 (subject to completion of the Capital Raise). Based on these current timeline expectations,
interim data is expected in the second half of 2021 which is likely to include safety data and potentially early
efficacy indicators. A more extensive trial result read out is expected around the end of 2022.
Avidmab
The Company has entered into three non-exclusive research agreements with leading antibody technology
companies in Europe, the USA and China to evaluate the Company’s anti-TaG mAbs including those
enhanced with the AvidiMab™ technology. TaGs can be targeted by several other tumour cell killing
approaches, including antibody drug conjugates (ADC), redirected T-cells, and also adoptive cell therapies
such as chimeric antigen receptor (CAR) T cells. Under the terms of the collaboration and research
agreements, Scancell and its partners will evaluate the potential of the anti-TaG mAbs, in these various
formats. The Company expects these collaboration and research agreements could transition into potential
partnerships. Advanced commercial discussions are currently underway with a global biotech with initial
commercial collaboration potentially to be in the form of granting a partner an option to a future licence.
Looking good, I suggest the Next 12 months will transform Scancell with Key Data on both SCIB1 and Modi1 starting to generate data
Not mentioned SCIB2 .. i assume its under the same issues as SCIB1 with Covid and is Subject to CRUK organisation not Scancell
Lets Hope Avidmab comes through first to Kick start what we have all expected and Held our shares despite being dragged down by "Funds Active sells due to them getting into trouble"
Sign In
Follow the stocks
